Canara Bank reported a 33.19% year-on-year (YoY) rise in net profit, reaching ₹5,004 crore for the quarter ended March 31, 2025.

• Operating profit stood at ₹8,284 crore, up 12.14% YoY.

• Fee-based income grew 20.30% YoY to ₹2,335 crore.

• Earnings per share increased by 16.98%.

• The Board has recommended a final dividend of ₹4 per share (200% of the ₹2 face value), up from 161% last year.

Business Performance

• Global business rose by 11.32% YoY to ₹25,30,215 crore.

• Total deposits increased by 11.01% to ₹14,56,883 crore.

• Gross advances climbed 11.74% to ₹10,73,332 crore.

• Domestic deposits stood at ₹13,31,137 crore, up 9.56%.

• Domestic advances rose to ₹10,08,671 crore, up 11.06%.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Retail and RAM Credit Growth

• RAM credit (Retail, Agriculture, MSME) grew 13.23% YoY to ₹6,10,127 crore.

• Retail lending jumped 42.80% YoY to ₹2,23,366 crore.
  • Housing loans grew by 13.57% to ₹1,06,167 crore.

  • Vehicle loans increased by 19.63%.

Asset Quality Improvement

• Gross NPA ratio improved to 2.94%, down from 4.23% in March 2024.

• Net NPA ratio improved to 0.70%, down from 1.27%.

• Provision Coverage Ratio (PCR) rose to 92.70%, an improvement of 360 basis points.

• Credit cost improved to 0.92%, and slippage ratio to 0.90%.

Capital Adequacy

• Capital Adequacy Ratio (CRAR) was at 16.33%:
  • CET1: 12.03%

  • Tier-I: 14.37%

  • Tier-II: 1.96%

Financial Inclusion and Priority Sector Lending

The bank exceeded all RBI-mandated norms for lending to priority sectors:

• 42.36% of credit to priority sector (norm: 40%)

• 20.05% to agriculture (norm: 18%)

• 13.42% to small/marginal farmers (norm: 10%)

• 19.25% to weaker sections (norm: 12%)

• 9.73% to micro enterprises (norm: 7.5%)

• 16.25% to non-corporate farmers (norm: 13.78%)

Branch and ATM Network

As of March 31, 2025, the bank had:

• 9,849 branches: 3,139 rural, 2,900 semi-urban, 1,944 urban, and 1,866 metro.

• 9,579 ATMs

• 4 overseas branches: London, New York, Dubai, and GIFT City (India)

About Canara Bank

Canara Bank is a leading public sector bank headquartered in Bengaluru, India. It was originally founded in 1906 in Mangaluru by Ammembal Subba Rao Pai. The bank became a part of the nationalised banking sector in 1969. Today, Canara Bank also operates international branches in cities like London, Dubai, and New York.

As of May 8, 2:01 PM IST, Canara Bank share price was trading at ₹96.49, up 3.01% for the day. The stock opened at ₹94.39 and touched an intraday high of ₹98.17 and a low of ₹92.93. The company has a market capitalisation of ₹87,510 crore, a price-to-earnings (P/E) ratio of 5.33, and a dividend yield of 3.34%. The stock’s 52-week high is ₹128.90, while the 52-week low is ₹78.60. The quarterly dividend amount currently stands at ₹0.81 per share.

Conclusion

Canara Bank’s strong Q4 performance reflects its sustained focus on credit growth, asset quality improvement, and profitability. With robust retail lending and stable fundamentals, the bank is well-positioned for continued growth in FY26.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.       

APL Apollo Tubes share price jumped nearly 3% on Thursday, reaching an intraday high of ₹1,709.90 after the company posted strong results for Q4 FY25. By 11:30 AM, the stock was trading at ₹1,699 on the NSE, up 2.18%. Meanwhile, the Nifty50 index remained flat at 24,413. The stock is trading just 1% below its 52-week high of ₹1,728.95, recorded on May 22, 2024. The company’s market cap stood at ₹47,062.62 crore. So far in 2025, the stock has gained about 6%, outperforming the Nifty50’s 3.2% rise.

Q4 FY25 Financial Highlights

APL Apollo Tubes posted a net profit of ₹293 crore for Q4 FY25, marking a 72% year-on-year (YoY) increase from ₹170.4 crore in the same quarter last year. Revenue rose by 15.6% YoY to ₹5,508.6 crore from ₹4,765.7 crore. The company’s EBITDA (earnings before interest, taxes, depreciation, and amortisation) came in at ₹413.7 crore, up 47.5% compared to ₹280.4 crore in Q4 FY24.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Dividend Announcement

APL Apollo’s board has declared a final dividend of ₹5.75 per share (on a face value of ₹2) for FY25.

About APL Apollo Tubes

APL Apollo Tubes is India’s largest manufacturer of structural steel tubes and is headquartered in Delhi. It runs 10 manufacturing plants across the country. The company makes over 1,500 different products including MS Black Pipes, Galvanised Tubes, Pre-Galvanised Tubes, Structural ERW Steel Tubes, and Hollow Sections. Its products serve sectors such as urban infrastructure, housing, irrigation, solar energy, greenhouses, and general engineering.

Conclusion

APL Apollo Tubes’ strong Q4 performance reflects robust demand, improved margins, and efficient operations. With healthy growth and a dividend boost, the company continues to reinforce its leadership in the structural steel segment, making it a stock to watch in the infrastructure and construction space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.       

Mastek, a leading digital engineering and cloud transformation company, has announced a strategic partnership with Zulekha Healthcare Group, one of the largest private healthcare providers in the UAE. The collaboration aims to enhance Zulekha’s operations by implementing Oracle Fusion Cloud solutions integrated with Oracle Health (Cerner).

Goal: Patient-Centred Innovation

This digital upgrade supports Zulekha’s “Patient First” approach. The new system will help improve clinical workflows, boost operational efficiency, increase financial agility, and reduce manual processes. It will also strengthen regulatory compliance and support better decision-making through data insights.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

About Zulekha Healthcare Group

Zulekha Healthcare is a well-known healthcare group in the UAE, employing over 2,500 people including 300+ doctors and 600+ nurses. The group runs 2 hospitals with a total of 285 beds, offering a wide range of medical and surgical treatments. It also manages a smart medical fitness centre for services like visa medicals, vaccinations, and health certifications.

Why Mastek Was Chosen

Zulekha selected Mastek due to its global reputation as a trusted Oracle partner and its expertise in healthcare digital solutions. Mastek has completed over 1,500 Oracle Cloud implementations in 40+ countries and offers more than 100 industry-specific solutions. With a team of over 2,000 skilled consultants, Mastek will fully integrate the new Oracle Cloud system with Zulekha’s existing hospital management and revenue systems.

Taher Shams, Managing Director of Zulekha Healthcare Group, said, “Our partnership with Mastek is a big step in our digital journey. The Oracle Fusion Cloud will help us become more agile, make smarter decisions, and ensure strong data security for better patient care.”

About Mastek

Mastek is a global company that delivers enterprise AI, digital, and cloud solutions, helping clients get long-term value from their technology investments. With a presence in over 40 countries and a team of 5,000+ professionals, Mastek works with major technology partners like Oracle, Salesforce, Microsoft, AWS, Snowflake, and Databricks. 

As of 1:09 PM IST on May 8, Mastek share price is trading at ₹2,180.90, up ₹86.50 or 4.13% for the day. The stock opened at ₹2,100.00, hit an intraday high of ₹2,223.00 and a low of ₹2,091.00. Mastek has a market capitalisation of ₹6,750 crore and a price-to-earnings (P/E) ratio of 18.08. The stock’s 52-week high is ₹3,375.00, while the 52-week low stands at ₹1,887.00.

About Zulekha Healthcare Group

Zulekha Healthcare Group is one of the top-ranked healthcare providers in the UAE and has been recognised by Newsweek as one of the World’s Best Hospitals. The group runs two major hospitals in Dubai and Sharjah, along with several medical centres and pharmacies. 

Conclusion

This collaboration between Mastek and Zulekha Healthcare marks a significant milestone in healthcare innovation in the UAE. By embracing advanced Oracle Cloud technologies and streamlining systems, Zulekha is setting new standards in delivering efficient, secure, and patient-centric care. This partnership reflects the growing trend of digital transformation in the healthcare sector aimed at enhancing operational excellence and patient outcomes.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.       

Zaggle Prepaid Ocean Services share price saw a strong rise of 9.2% on Thursday, reaching an intraday high of ₹355 per share on the BSE. The rally came after the company announced that it had entered into a significant agreement with Grant Thornton Bharat LLP.

Stock Performance and Market Overview

At 11:45 AM, Zaggle shares were trading 7.46% higher at ₹349.10 per share on the BSE. In comparison, the benchmark BSE Sensex was nearly flat, up just 0.05% at 80,789.18.
Zaggle’s total market capitalisation at that time stood at ₹4,685.1 crore.

Over the past year, Zaggle’s stock has gained 11%, slightly outperforming the Sensex, which has risen 10% during the same period. The stock’s 52-week high was ₹597, reached on December 17, 2024, and the 52-week low was ₹235 per share.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Details of the Agreement With Grant Thornton Bharat

The company informed the stock exchanges that it had signed an agreement with Grant Thornton Bharat LLP. This partnership will be carried out over the next 3 years. As per the agreement, Grant Thornton will offer Zaggle’s Spend Management platform to its corporate clients and large enterprises.

The Spend Management platform is designed to help companies better manage their expenses and streamline financial operations. This collaboration is expected to increase the adoption of Zaggle’s software solutions in the enterprise segment and strengthen its position in the market.

About Zaggle Prepaid Ocean Services

Zaggle was established in 2011 and operates as a leading FinTech company in India. It offers a wide range of financial technology products and services and is well-known in the area of spend management.

The company has issued over 50 million prepaid cards in partnership with leading banks and currently serves a large user base of more than 3 million people.

Zaggle’s portfolio includes a variety of SaaS-based platforms, offering solutions for expense management, digital payments, and rewards. These products are designed to meet the needs of both enterprises and individual users across multiple touchpoints.

Conclusion

Zaggle’s new partnership with Grant Thornton Bharat marks a strategic move to boost the reach of its Spend Management platform across India’s corporate landscape. With a solid market presence and a diverse fintech portfolio, Zaggle is well-positioned to capitalise on growing demand for digital expense and payment solutions in the enterprise sector. Investors responded positively, indicating confidence in the company’s growth trajectory through strategic collaborations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.       

Sonata Software’s share price rose nearly 5% on Thursday, hitting an intraday high of ₹414.95 on the BSE after the company reported solid Q4 results.

Stock Performance and Market Overview

At around 9:51 AM, Sonata share price was trading at ₹401.70, up 1.22% from the previous close. In comparison, the BSE Sensex was almost flat, up just 0.01% at 80,752.04. The company’s market capitalisation stood at ₹11,264.66 crore.

Over the past year, Sonata’s shares have declined 26%, even as the Sensex gained 10%. The stock’s 52-week high is ₹762, and the low is ₹286.4. Its all-time high was ₹867.10 on February 27, 2024.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Q4 FY25 Results Highlights

Sonata Software posted a modest 2% growth in consolidated net profit to ₹108 crore in Q4 FY25, compared to ₹105 crore in Q3. However, revenue grew strongly by 19%, rising to ₹2,617 crore from ₹2,192 crore in the previous quarter.

The company secured 2 major contracts during the quarter:

• A US-based Technology Outsourcing deal.

• A Cloud and Data Transformation project with a multinational financial company in the US.

Dividend Announcement

The board of directors (BoD) recommended a final dividend of ₹4.40 per equity share (440% on the face value of ₹1) for the financial year ended March 31, 2025.

About Sonata Software

Sonata Software is a global IT services company with a revenue of $1 billion. It focuses on digital transformation using its unique Platformation.AI approach. The company offers modernisation services across key areas like Cloud, Data, Microsoft Dynamics, Automation, Cybersecurity, Generative AI, Microsoft Fabric, and other next-gen technologies.

Conclusion

Sonata Software’s steady earnings growth, strong revenue surge, and strategic US deal wins signal a positive outlook. The dividend payout adds to investor confidence, making the stock a strong contender in the tech space despite recent underperformance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.  

 

Symphony Ltd share price surged over 10% in morning trading on Thursday following the release of its Q4 FY25 results and a dividend announcement. The results were published after market hours on Wednesday.

Q4 FY25 Results Show Strong Growth

In the January–March quarter (Q4 FY25), Symphony posted a 64.6% jump in its consolidated net profit to ₹79 crore, compared to ₹48 crore in the same quarter last year. Revenue for the quarter also saw a strong increase, rising 47% year-on-year to ₹488 crore, up from ₹332 crore. This growth was driven by higher sales, better market reach, and improved efficiency.

The company’s EBITDA rose sharply by 87.7% to ₹107 crore from ₹57 crore. Margins improved to 22%, up from 17.2% a year earlier.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Record-Breaking Year for Symphony

Symphony noted that it achieved several major milestones in FY25. It recorded its highest-ever March quarter revenue and crossed ₹1,500 crore in annual consolidated revenue, reaching ₹1,576 crore — a 36% increase from last year.

On a standalone basis, it crossed the ₹1,000 crore mark for the first time, with ₹1,182 crore in revenue — a 49% year-on-year rise.

Dividend Announcement

The Board of Directors (BoD) has recommended a final dividend of ₹8 per share (face value ₹2 each) for FY25. This final dividend is subject to shareholder approval at the upcoming AGM.
If approved, Symphony will distribute a total of ₹178.4 crore as dividends, which is 84% of its full-year consolidated profit.

Share Price Reaction

As of May 8, Symphony share price stands at ₹1,310.70, up ₹110.80 or 9.23% for the day. The stock opened at ₹1,319.00, reached a high of ₹1,347.90, and a low of ₹1,291.40. The company has a market capitalisation of ₹9,000 crore, a P/E ratio of 49.32, and a dividend yield of 0.99%. Its 52-week high is ₹1,880.95 and the 52-week low is ₹913.00. The quarterly dividend amount is ₹3.24 per share.

Conclusion

Symphony’s strong financial performance and shareholder-friendly dividend policy have clearly impressed investors, resulting in a sharp surge in share price. With record-breaking revenue milestones and improved profitability, the company appears well-positioned for continued growth in the coming fiscal year.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.  

 

Reliance Power announced on Wednesday that it has successfully raised ₹348.15 crore by issuing shares on a preferential basis.

Breakup of Share Allotment

The company issued a total of 10.55 crore fully paid equity shares at a price of ₹33 per share (including a ₹23 premium per share).

• 9.55 crore shares were allotted to Reliance Infrastructure, the company’s promoter.

• 1 crore shares were allotted to Basera Home Finance Pvt Ltd, a public entity.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date. 

Funds to Support Renewable Energy Growth

Reliance Power said this capital will help boost its growth in the renewable energy sector. The company aims to use this fund infusion to further strengthen its business in clean energy.

Previous Fundraising Through Warrants

Earlier, in October 2024, the company issued 46.20 crore warrants worth ₹1,525 crore.

• Investors paid 25% upfront.

• The remaining 75% will be paid within 18 months.

• Once fully paid, these warrants can be converted into equity shares in the company.

Strong Financial Position With Zero Bank Debt

Reliance Power also highlighted that it currently has zero bank debt, which means it has not borrowed any money from banks. This gives the company financial strength and flexibility, allowing it to focus on sustainable growth and seize new business opportunities.

About Reliance Power

Part of the Reliance Group, Reliance Power is one of India’s major private power generation companies. It operates a total of 5,305 megawatts, including the 3,960 MW Sasan Ultra Mega Power Project.

As of 10:13 AM IST on May 8, Reliance Power share price is trading at ₹39.45, up ₹0.34 or 0.87% for the day. The stock opened at ₹39.70 and has touched a high of ₹40.10 and a low of ₹39.11 so far. The company has a market capitalisation of ₹15,840 crore and a price-to-earnings (P/E) ratio of 6.58. It currently does not offer a dividend yield. Over the past 52 weeks, the stock has traded between a low of ₹23.30 and a high of ₹53.64.

Conclusion

This latest fund infusion marks another step in Reliance Power’s strategy to expand its presence in the renewable energy space. With a debt-free balance sheet and strong promoter backing, the company is well-positioned to pursue future growth opportunities.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                          

                                          

Investments in securities market are subject to market risks, read all the related documents carefully before investing.       

Shares of Bajaj Finance, Coforge, Laurus Labs, Bank of Maharashtra, and Transformers and Rectifiers (India) are likely to remain in focus today, Thursday, May 8, 2025. These companies have recently announced dividend rewards for their shareholders. A dividend is a part of a company’s profit that is distributed among its shareholders. It is often considered a source of passive income for investors, as it provides regular income without the need to sell shares.

Ex-Dividend Date: What It Means for Investors

According to data available on the Bombay Stock Exchange (BSE), these companies are scheduled to trade ex-dividend on May 9, 2025. The ex-dividend date is important because it is the date from which the stock will trade without the value of the upcoming dividend. In simple terms, if investors want to be eligible to receive the declared dividend, they need to buy and hold the stock before the ex-dividend date. After this date, new buyers will not be eligible for the dividend. The final list of eligible shareholders is determined based on the record date, which is the same as the ex-date—May 9, 2025—for all the companies mentioned.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date.

Details of Dividend Announcements

Among all the companies announcing dividends, Coforge has declared the highest dividend. The company has announced an interim dividend of ₹19 per share. It has also set May 9, 2025, as the record date for determining eligible shareholders who will receive the dividend.

Following Coforge, Bajaj Finance has announced a special dividend of ₹12 per share, with the same record date of May 9, 2025.

Other companies joining the dividend list include:

• Bank of Maharashtra: The public sector bank has announced a final dividend of ₹1.50 per share.

• Laurus Labs: The pharmaceutical company has declared an interim dividend of ₹0.80 per share.

• Transformers and Rectifiers (India): The company has announced a final dividend of ₹0.20 per share.

All these companies have their record dates set as May 9, 2025, meaning shareholders on record on that day will receive the announced dividends.

Other Notable Dividend Announcements

In addition to the companies listed above, 2 other firms will also be closely watched by investors as they trade ex-dividend on May 8, 2025:

• Oracle Financial Services Software: This company has declared a very high interim dividend of ₹265 per share, making it one of the top dividend-paying stocks currently.

• Gravita India: The company has announced an interim dividend of ₹6.35 per share.

Conclusion

These dividend announcements are likely to draw attention from investors who are looking for income-generating opportunities in the stock market. Dividend-paying stocks can be attractive during uncertain times as they offer a steady return, and today’s market activity is expected to reflect that investor interest.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                         

                                         

Investments in securities market are subject to market risks, read all the related documents carefully before investing.      

Indian markets are likely to be impacted today due to global cues, the US Fed’s decision to maintain interest rates, and rising border tensions between India and Pakistan after ‘Operation Sindoor’. At around 7:36 AM, GIFT Nifty futures were down 45 points at 24,416.

In the previous trading session, the Sensex rose by 105.71 points to close at 80,746.78, while the Nifty50 gained 34.80 points to settle at 24,414.40.

Global Market Snapshot

• Asia-Pacific:
  • CSI 300 (China): +0.16%

  • Shanghai Composite: -0.01%

  • Hang Seng (Hong Kong): -0.45%

  • Nikkei (Japan): +0.07%

  • ASX 200 (Australia): +0.12%

• Wall Street:
  US stocks closed higher led by chipmakers after reports that AI chip restrictions might be eased:
  • Nasdaq: +0.27%

  • S&P 500: +0.43%

  • Dow Jones: +0.70%

Key Earnings to Watch Today

Companies releasing Q4 results today include:

Asian Paints, Bharat Forge, Biocon, Britannia, Canara Bank, Chambal Fertilisers, Escorts Kubota, Ideaforge, IIFL Finance, L&T, MCX, Titan, Sula Vineyards, Union Bank of India, Zee Entertainment, and others.

Read More, Anand Rathi Wealth Declared Final Dividend: Set May 9 as Record Date.

Q4 FY25 Results Announced

• Coal India

Coal India’s Net profit rose 12% YoY to ₹9,593 crore, while revenue dropped 1% to ₹37,825 crore.

• Dabur

Dabur Net profit declined 8.3% YoY to ₹320 crore. Revenue was flat at ₹2,830 crore.

• Voltas

Voltas Net profit more than doubled to ₹236 crore. Declared ₹7/share dividend for FY25.

• Punjab National Bank (PNB)

Punjab National Bank Net profit surged 51.7% YoY to ₹4,567 crore. Gross NPAs fell significantly.

• Tata Chemicals

Tata Chemicals posted a loss of ₹67 crore, improving from a ₹818 crore loss a year ago.

Stocks in News

• PB Fintech

PB Fintech, the parent of Policybazaar has raised $218 million for its new healthcare venture, marking its debut in the healthcare sector.

• Reliance Power

Reliance Power issued over 10.55 crore shares worth ₹348 crore to Reliance Infrastructure and Basera Home Finance after warrant conversions.

• Gensol Engineering

Gensol Engineering SAT rejected its plea for interim relief in an alleged fund misuse case.

• TCS

TCS leased 10.2 lakh sq ft of office space in Hyderabad’s business hub for ₹4.37 crore per month.

Conclusion

Markets may see cautious trading today amid geopolitical tensions and mixed global signals. Investors should keep an eye on Q4 earnings and key stock movements for trading cues.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                        

                                        

Investments in securities market are subject to market risks, read all the related documents carefully before investing.        

 

India stands as the world’s leading supplier of generic medicines, well-known for producing cost-effective vaccines and pharmaceutical products. Ranking third globally in terms of production volume, the Indian pharmaceutical sector has achieved a compound annual growth rate (CAGR) of 9.43% over the past 9 years. It also boasts the highest number of USFDA-approved manufacturing facilities outside the US, underscoring its global quality standards.

The industry contributes significantly to global healthcare, supplying 50% of vaccines worldwide, 40% of generics used in the U.S., and 25% of those in the U.K. Domestically, the sector comprises approximately 3,000 pharmaceutical companies and 10,500 manufacturing units, making up about 1.72% of India’s GDP.

India is also the dominant global source of antiretroviral drugs used in AIDS treatment, fulfilling over 80% of global demand. These achievements have earned India the title of the “pharmacy of the world.” While it ranks third globally in terms of production volume, it is 14th by market value.

Looking ahead, the Indian pharmaceutical market is projected to reach $130 billion by 2030. Meanwhile, the global pharma industry surpassed USD 1 trillion in market size in 2023.

Now, let’s look at the top Indian pharmaceutical stocks for May 2025, evaluated based on their 5-year CAGR, 1-year return, and market capitalisation.

Top Pharma Stocks in India in May 2025 – 5yr CAGR Basis

Note: The list of top pharma stocks in India in May here is picked from the Nifty 500 universe and is sorted as per 5-year CAGR as of May 07, 2025. 

Read More, Best Drone Stocks in India in May 2025: Zen Tech, RattanIndia, HAL and More – 5Yr CAGR Basis.  

Overview of Best Pharma Stocks in India

1. Neuland Laboratories

Neuland Laboratories specialises in the production and sale of bulk drugs, serving both domestic and global markets.

In Q3FY25, Neuland Laboratories reported a slight 1.8% year-on-year rise in total income to ₹401.9 crore, and a strong 27.5% sequential growth. However, EBITDA dropped 26.4% YoY to ₹90.3 crore, though it improved 37.5% from the previous quarter. 

Key metrics: 

• Earning per share (EPS): ₹233.28
• Return on equity (ROE): 21.56%

2. Suven Pharmaceuticals Ltd

Based in Hyderabad, this CDMO (Contract Development and Manufacturing Organization) serves leading global pharmaceutical and fine chemical companies in their NCE (New Chemical Entity) development efforts. 

For the quarter ended December 2024, the company reported a revenue of ₹275.39 crore, up from ₹236.06 crore in September 2024. Its net profit for the December quarter stood at ₹86.35 crore, compared to ₹76.33 crore in the previous quarter. 

Key metrics: 

• EPS: ₹11.05
• ROE: 12.75%

3. Laurus Labs

Founded in 2005, Laurus Labs is a research-focused pharmaceutical and biotechnology firm that holds a prominent global position in manufacturing key Active Pharmaceutical Ingredients (APIs), particularly for anti-retroviral, oncology, cardiovascular, and gastroenterology therapies, including high-potency APIs.

In the quarter ending December 2024, Laurus Labs reported a revenue of ₹1,265.19 crore, up from ₹1,184.85 crore in September 2024, contributing to a total revenue of ₹4,812.39 crore for FY 2023–24. The net profit for December stood at ₹57.27 crore, rising from ₹42.44 crore in the previous quarter, with a cumulative net profit of ₹223.70 crore for the fiscal year.

Key metrics: 

• EPS: ₹4.63
• ROE: 5.85%

4. Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd specialises in the manufacturing and procurement of APIs and finished formulations. The company is also involved in R&D and clinical research, with a strong presence across Latin America, Africa, the USA, and several other countries.

Caplin Point Laboratories reported a revenue of ₹185.23 crore in December 2024, down from ₹207.93 crore in September 2024, while the revenue for FY 2023–24 stood at ₹625.09 crore. The net profit for December 2024 was ₹74.71 crore, compared to ₹105.74 crore in September 2024, with a total net profit of ₹283.71 crore for the fiscal year.

Key metrics: 

• EPS: ₹42.48
• ROE: 21.03%

5. Wockhardt Ltd

Wockhardt is an international pharmaceutical and biotechnology company involved in producing finished dosage forms, injectables, biopharmaceuticals, oral medications, and topical products such as creams and ointments.

Wockhardt reported a revenue of ₹325 crore in December 2024, down from ₹370 crore in September 2024, while the net loss narrowed to ₹22 crore from ₹36 crore in the previous quarter. For FY 2023-24, the company posted a total revenue of ₹1,154 crore and a net loss of ₹422 crore.

Key metrics: 

• EPS: -₹10.95
• ROE: -10.08%

 

Top Pharma Stocks in India in May 2025 – Market Cap Basis

Note: The list of top pharma stocks in India in May here is picked from the Nifty 500 universe and is sorted as per market cap as of May 07, 2025. 

Top Pharma Stocks in India in May 2025 – 1-yr Return Basis

Note: The list of top pharma stocks in India in May here is picked from the Nifty 500 universe and is sorted as per 1-year return as of May 07, 2025. 

 

Key Factors to Evaluate Before Investing in Indian Pharma Stocks

1. Healthcare Infrastructure

The development of healthcare infrastructure in India plays a crucial role in shaping the pharmaceutical sector. As hospitals, clinics, and other medical services expand, the demand for pharmaceutical products rises, offering growth prospects for pharma companies.

2. Rising Demand

Demand for medicines is driven by several factors, including an ageing population, increasing healthcare expenditure, and the emergence of lifestyle and infectious diseases. Understanding both current trends and future projections is important when assessing the growth potential of pharmaceutical stocks.

3. Industry Competition and Consolidation

India’s pharmaceutical industry is highly competitive, with firms frequently engaging in mergers and acquisitions to strengthen their position. Investors should examine a company’s market share, recent performance, and long-term growth strategy to make well-informed investment decisions.

4. Focus on Research and Development

Pharma companies invest significantly in R&D to discover and launch new drugs. Analysing a company’s investment in research and its pipeline of upcoming products can provide insight into its innovation potential and future revenue drivers.

Conclusion

The Indian pharmaceutical industry presents attractive investment opportunities due to its strong role in global trade. However, investors should be cautious of risks such as regulatory changes, especially those affecting pricing policies and exports. Heavy reliance on markets like the US also means that FDA inspections and policy shifts can impact performance. Additionally, as a large portion of revenues comes from exports, currency volatility may affect earnings. Thorough analysis of these factors is essential before investing in the pharma space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.                                       

                                       

Investments in securities market are subject to market risks, read all the related documents carefully before investing.